Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry
The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field.
Top performers in last week's mid-cap stocks: Oklo Inc., Tempus AI, Himax Tech, Super Group, NuScale Power, WNS Holdings, Guardant Health, Rigetti Computing.
Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earnings
Tempus AI Inc (NASDAQTEM) shares are trading higher Wednesday. The stock appears to be moving on continued momentum from Tuesday's session. Here's a look at what you need to know.
TEM surged 35% on Tuesday, fueled by the launch of its AI-powered health app Olivia and news of Nancy Pelosi's disclosed call option position in the stock.
TempusAI’s olivia includes features such as smart profile summary, AI-enabled notetaker, medical image sharing, health monitoring and direct data import.
Tempus AI Inc (NASDAQTEM) shares are trading higher Tuesday after former House Speaker Nancy Pelosi disclosed a new position in the technology company.
Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights.
Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares.
Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available.
Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneously advancing research to bring new drugs to market. This latest iteration now applies Tempus’ proprietary Large Language Model (LLM) Agent Infrastructure (Agent Builder), which adapts LLMs to work on unstructured, multimodal healthcare data to improve clinical care and research.
Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.
Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.
Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.
